may be administered together with specifically an anti-VEGF agent, more specifically an anti-VEGF antibody. For combined administration with the other agent, both agents may be administered together in a single composition, or may be administered in separate compositions as part of a combined therapy.

Examples

[0053] In order to understand the present invention deeper, the experimental results leading to the present invention are shown in each of Reference Examples, specific contents of the invention are shown in Examples, and they are described in detail. The present invention is not limited to the matters described in these Reference Examples or Examples.

[0054] (Example 1) Effects on Laser-induced Choroidal Neovascularization (CNV) Model

(1) Evaluation of Fluorescein Angiography (FA) Grade

A Mydrin-P ophthalmic solution (Santen Pharmaceutical Co., Ltd., Mydrin is a trademark) was dropped into the right eye of 8-week-old mice (Japan SLC, Inc., C57BL/6J strain) to cause mydriasis. A solution obtained by diluting a 7:1 mixed anesthetic solution of ketamine and xylazine 10-fold with physiological saline was administered at 10 mL/kg into the femoral muscle. After that, a 0.1% Hyalein (trademark) ophthalmic solution (Santen Pharmaceutical Co., Ltd.) was dropped into the eye so as to prevent the eyeball from drying.

This shows that Compound 5 has reduced the permeability between the retinal vascular endothelial cells.

[0082] (Example 10) Permeability-reducing Action of Compound 6 on Human Retinal Vascular Endothelial Cells

The permeability-reducing action of Compound 6 on human retinal vascular endothelial cells was measured in the same manner as in Example 5. The results are shown in FIG. 12. Compound 6 significantly decreased the amount of FITC-dextran permeating the lower chamber.

This shows that Compound 6 has reduced the permeability between the retinal vascular endothelial cells.

[0083] (Example 11) Permeability-reducing Action of Compound 7 on Human Retinal Vascular Endothelial Cells

The permeability-reducing action of Compound 7 on human retinal vascular endothelial cells was measured in the same manner as in Example 5. The results are shown in FIG. 13. Compound 7 significantly decreased the amount of FITC-dextran permeating the lower chamber.

This shows that Compound 7 has reduced the permeability between the retinal vascular endothelial cells.

[0084] (Comparative Example 1) Effects of FTY720 on CNV Model

(1) Evaluation of Fluorescein Angiography (FA) Grade

A Mydrin-P ophthalmic solution (Santen Pharmaceutical Co., Ltd., Mydrin is a trademark) was dropped into one eye of 8-week-old mice (Japan SLC, Inc., C57BL/6J strain) to cause mydriasis, and